Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Drug Profile

Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Alternative Names: Cobicistat/elvitegravir/emtricitabine/TAF; Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Emtricitabine/cobicistat/elvitegravir/tenofovir alafenamide; Genvoya; Tenofovir alafenamide/cobicistat/elvitegravir/emtricitabine

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Quinolones; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; HIV integrase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 31 Jul 2017 Gilead Sciences completes a phase III trial in HIV-1 infections (Treatment experienced) in Uganda, Thailand, Dominican Republic, Russia, United Kingdom, USA, Germany (PO) (EudraCT2013-002830-19) (NCT01967940)
  • 04 May 2017 Launched for HIV-1 infections (In adolescents, Treatment-experienced, In adults) in Canada (PO)
  • 04 May 2017 Launched for HIV-1 infections (In adolescents, Treatment-naive, In adults) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top